UroGen Pharma Ltd. Finance Lease, Right-of-Use Asset, Amortization
UroGen Pharma Ltd. (URGN) reported Finance Lease, Right-of-Use Asset, Amortization of $440.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-05
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $440.00K, a 45.70% increase year-over-year.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $427.00K, a 96.77% increase year-over-year.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $455.00K, a 1163.89% increase year-over-year.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $382.00K.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for fiscal 2025 was $1.36M, a 3666.67% increase from fiscal 2024.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for fiscal 2024 was $36.00K.
- UroGen Pharma Ltd. finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $440.00K 10-Q · filed 2026-08-05 | $867.00K 10-Q · filed 2026-08-05 | $1.32M derived: sum of 3 quarters · filed 2026-08-05 | $1.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $427.00K 10-Q · filed 2026-05-06 | $882.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.26M derived: sum of 3 quarters · filed 2026-05-06 | $1.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $837.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.14M derived: sum of 3 quarters · filed 2026-08-05 | $1.36M 10-K · filed 2026-03-02 |
| 2025-09-30 | $382.00K 10-Q · filed 2025-11-06 | $684.00K derived: sum of 2 quarters · filed 2026-08-05 | $901.00K 10-Q · filed 2025-11-06 | $937.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $302.00K 10-Q · filed 2026-08-05 | $519.00K 10-Q · filed 2026-08-05 | $555.00K derived: sum of 3 quarters · filed 2026-08-05 | $555.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $217.00K 10-Q · filed 2026-05-06 | $253.00K derived: sum of 2 quarters · filed 2026-05-06 | $253.00K derived: sum of 3 quarters · filed 2026-05-06 | $253.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $36.00K derived: sum of 2 quarters · filed 2026-03-02 | $36.00K derived: sum of 3 quarters · filed 2026-03-02 | $36.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |